investorscraft@gmail.com

Stock Analysis & ValuationEnlivex Therapeutics Ltd. (ENLV)

Previous Close
$1.05
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

14 Einstein Street
Ness Ziona 7403618
IL
Phone: 972 8 662 3301
Industry: Biotechnology
Sector: Healthcare
CEO: Oren Hershkovitz
Full Time Employees: 71

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

HomeMenuAccount